IL179015A0 - Compressed tablet comprising valsartan - Google Patents

Compressed tablet comprising valsartan

Info

Publication number
IL179015A0
IL179015A0 IL179015A IL17901506A IL179015A0 IL 179015 A0 IL179015 A0 IL 179015A0 IL 179015 A IL179015 A IL 179015A IL 17901506 A IL17901506 A IL 17901506A IL 179015 A0 IL179015 A0 IL 179015A0
Authority
IL
Israel
Prior art keywords
valsartan
compressed tablet
receptors
increase
epithelia
Prior art date
Application number
IL179015A
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26152118&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL179015(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP98811258A external-priority patent/EP1013273A1/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL179015A0 publication Critical patent/IL179015A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the use of an AT 1 receptor antagonist or or an AT 2 receptor modulator, respectively, or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT 1 receptors in the sub-epithelial area or increase of AT 2 receptors in the epithelia.
IL179015A 1998-12-23 2006-11-02 Compressed tablet comprising valsartan IL179015A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98811258A EP1013273A1 (en) 1998-12-23 1998-12-23 Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
EP98811257 1998-12-23
PCT/EP1999/010330 WO2000038676A1 (en) 1998-12-23 1999-12-22 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors

Publications (1)

Publication Number Publication Date
IL179015A0 true IL179015A0 (en) 2007-03-08

Family

ID=26152118

Family Applications (5)

Application Number Title Priority Date Filing Date
IL14323399A IL143233A0 (en) 1998-12-23 1999-12-22 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
IL143233A IL143233A (en) 1998-12-23 2001-05-17 Use of valsartan or a pharmaceutically acceptable salt thereof for producing a pharmaceutical preparation for the treatment of invasive lung and invasive breast cancer
IL179015A IL179015A0 (en) 1998-12-23 2006-11-02 Compressed tablet comprising valsartan
IL179017A IL179017A0 (en) 1998-12-23 2006-11-02 Solid oral dosage form comprising valsartan
IL179016A IL179016A0 (en) 1998-12-23 2006-11-02 Compressed tablet comprising valsarta

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL14323399A IL143233A0 (en) 1998-12-23 1999-12-22 Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
IL143233A IL143233A (en) 1998-12-23 2001-05-17 Use of valsartan or a pharmaceutically acceptable salt thereof for producing a pharmaceutical preparation for the treatment of invasive lung and invasive breast cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL179017A IL179017A0 (en) 1998-12-23 2006-11-02 Solid oral dosage form comprising valsartan
IL179016A IL179016A0 (en) 1998-12-23 2006-11-02 Compressed tablet comprising valsarta

Country Status (26)

Country Link
EP (3) EP1588706B1 (en)
JP (2) JP2002533390A (en)
KR (1) KR100646716B1 (en)
CN (2) CN1304000C (en)
AT (2) ATE354364T1 (en)
AU (4) AU3043000A (en)
BR (1) BR9916576A (en)
CA (2) CA2351357A1 (en)
CY (2) CY1106581T1 (en)
CZ (2) CZ293257B6 (en)
DE (1) DE69935249T2 (en)
DK (2) DK1140071T3 (en)
ES (2) ES2373556T3 (en)
HK (1) HK1038888B (en)
HU (1) HUP0104780A3 (en)
ID (1) ID29856A (en)
IL (5) IL143233A0 (en)
NO (2) NO328775B1 (en)
NZ (3) NZ553010A (en)
PL (1) PL199100B1 (en)
PT (2) PT1588706E (en)
RU (3) RU2271809C2 (en)
SI (2) SI1588706T1 (en)
SK (1) SK9132001A3 (en)
TR (7) TR200805275T2 (en)
WO (1) WO2000038676A1 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1296677A2 (en) * 2000-06-22 2003-04-02 Novartis AG Solid valsartan pharmaceutical compositions
JP4972847B2 (en) * 2000-10-11 2012-07-11 住友化学株式会社 Collagen accumulation inhibitor
WO2002083127A1 (en) * 2001-04-09 2002-10-24 Tokai University Educational System Protein modification-inhibitory compositions
DK1395566T3 (en) 2001-05-31 2008-01-07 Vicore Pharma Ab Tricyclic compounds useful as angiotensin II agonists
WO2003041739A1 (en) 2001-11-13 2003-05-22 Takeda Chemical Industries, Ltd. Anticaner agents
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SK50472005A3 (en) * 2003-11-03 2005-09-08 Zentiva, A. S. Tablet containing valsartan prepared via direct tabletting
AU2005318365B2 (en) 2004-12-24 2011-02-03 Krka, D.D., Novo Mesto Solid pharmaceutical composition comprising valsartan
NZ555334A (en) * 2004-12-24 2010-05-28 Spinifex Pharm Pty Ltd Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
GT200600371A (en) 2005-08-17 2007-03-21 SOLID DOSE FORMS OF VALSARTAN AND AMLODIPINE AND METHOD TO DO THE SAME
ES2246742B1 (en) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. USE OF A DERIVATIVE OF IMIDAZOLE.
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20110027358A1 (en) * 2007-03-29 2011-02-03 Rajesh Kshirsagar Valsartan tablet formulations
TR200703568A1 (en) 2007-05-24 2008-07-21 Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket� Valsartan formulations
MX2010003923A (en) 2007-10-09 2010-05-05 Novartis Ag Pharmaceutical formulation of valsartan.
MY153730A (en) * 2007-11-06 2015-03-13 Novartis Ag Dual-acting pharmaceutical compositions based on superstructures of angiotensin receptor antagonist/blocker (arb) and neutral endopeptidase (nep) inhibitor
US20110104166A1 (en) 2008-01-18 2011-05-05 Stankovic Konstantina M Methods and Compositions for Treating Polyps
GB0802931D0 (en) * 2008-02-18 2008-03-26 Queen Mary & Westfield College Synthetic scFv analogue to the 6313/G2 (anti angiotensin II type 1 receptor) monoclonal anitbody variable regions
EP2405899A2 (en) 2009-03-11 2012-01-18 Sanovel Ilaç Sanayi Ve Ticaret Anonim Sirketi Valsartan formulations
EP2536396B1 (en) 2010-02-16 2016-08-10 KRKA, D.D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
EP2455388A1 (en) 2010-11-23 2012-05-23 LanthioPep B.V. Novel angiotensin type 2 (AT2) receptor agonists and uses thereof.
CN102266307B (en) * 2011-08-01 2012-10-24 海南锦瑞制药股份有限公司 Valsartan capsules and preparation method thereof
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
EA018867B1 (en) * 2012-11-01 2013-11-29 Лаборатория Тютор С.А.С.И.Ф.И.А. Method of producing pharmaceutical composition and product therefrom
WO2021023698A1 (en) 2019-08-02 2021-02-11 Lanthiopep B.V Angiotensin type 2 (at2) receptor agonists for use in the treatment of cancer
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide
WO2024026528A1 (en) * 2022-08-02 2024-02-08 Dimerix Bioscience Pty Ltd Dosage regimen for the treatment of copd

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3146168A (en) 1962-04-10 1964-08-25 Fmc Corp Manufacture of pharmaceutical preparations containing cellulose crystallite aggregates
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
DE68916983T2 (en) * 1988-02-25 1995-01-19 Yamanouchi Europ Bv Process for the manufacture of pharmaceutical granules.
DK0403159T3 (en) 1989-06-14 2000-08-14 Smithkline Beecham Corp imidazolyl
IE70593B1 (en) 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
DE122007000050I1 (en) * 1990-02-19 2007-11-08 Novartis Ag acyl compounds
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
IE912956A1 (en) 1990-09-10 1992-03-11 Abbott Lab Angiotensin ii receptor antagonists
EP0551432A1 (en) 1990-10-02 1993-07-21 Warner-Lambert Company 4,5,6,7-tetrahydro-1h-imidazo 4,5-c]pyridine derivatives and analogues as angiotensin ii receptor antagonists
DE4038335A1 (en) * 1990-12-01 1992-06-04 Boehringer Mannheim Gmbh NEW PYRIDE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICINAL PRODUCTS
US5614519A (en) * 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
SI9210098B (en) * 1991-02-06 2000-06-30 Dr. Karl Thomae Benzimidazoles, drugs with this compounds, and process for their preparation
US5196537A (en) 1991-03-21 1993-03-23 G. D. Searle & Co. 5-apylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
GB9110636D0 (en) 1991-05-16 1991-07-03 Glaxo Group Ltd Chemical compounds
DE4132632A1 (en) * 1991-10-01 1993-04-08 Bayer Ag SUBSTITUTED IMIDAZOLYL-PROPENSAEUREDERIVATE
DE4309968A1 (en) * 1993-03-26 1994-09-29 Bayer Ag Phenylglycinamides of heterocyclic substituted phenylacetic acid derivatives
NZ251741A (en) 1992-04-13 1997-06-24 Zeneca Ltd Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity
EP0673369A1 (en) * 1992-12-11 1995-09-27 Novartis AG Substituted benzazepinones
KR950704280A (en) 1992-12-11 1995-11-17 베르너 발데크 Benzazepinone Derivatives
DE4309963A1 (en) * 1993-03-26 1994-09-29 Hubert Kamperschroer Barrel for the discharge of liquid manure
FR2716882B1 (en) * 1994-03-04 1996-04-05 Roussel Uclaf Use of imidazole derivatives for the treatment of conditions involving the AT1 and AT2 receptors of Angiotensin, some of these products, their preparation, pharmaceutical compositions.
DE4408497A1 (en) 1994-03-14 1995-09-21 Thomae Gmbh Dr K New bi:phenyl-methyl-benzimidazole derivs.
JPH09510225A (en) * 1994-03-17 1997-10-14 チバ−ガイギー アクチェンゲゼルシャフト Treatment of diabetic nephropathy with valsartan
DE4432860A1 (en) * 1994-09-15 1996-03-21 Merck Patent Gmbh imidazopyridines
PT853477E (en) 1995-10-06 2003-01-31 Novartis Ag AT1 RECEPTOR ANTAGONISTS FOR PREVENTION AND TREATMENT OF POS ISKEMIC RENAL INSUFFICIENCY AND FOR ISCHEMIC RIM PROTECTION
WO1997031624A1 (en) 1996-02-27 1997-09-04 Purdue Research Foundation Liposomal delivery system
PT883401E (en) * 1996-02-29 2003-03-31 Novartis Ag AT1 RECEPTOR ANTAGONIST FOR APOPTOSIS STIMULATION
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
DE19628617A1 (en) * 1996-07-16 1998-01-22 Basf Ag Direct tabletting aid
ES2552639T3 (en) * 1998-07-10 2015-12-01 Novartis Pharma Ag Combined use of valsartan and calcium channel blockers for therapeutic purposes
EP1146872B1 (en) 1999-01-26 2006-06-21 Novartis AG Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
EP1296677A2 (en) * 2000-06-22 2003-04-02 Novartis AG Solid valsartan pharmaceutical compositions
US20070123498A1 (en) 2003-10-17 2007-05-31 Shetty Suraj S Combination of organic compounds
JP2009018990A (en) 2005-10-25 2009-01-29 Univ Kurume Peptides originating in hepatitis c virus

Also Published As

Publication number Publication date
IL143233A0 (en) 2002-04-21
AU2009220022B2 (en) 2011-11-03
DK1140071T3 (en) 2007-06-04
ES2373556T3 (en) 2012-02-06
CA2351357A1 (en) 2000-07-06
KR20010089681A (en) 2001-10-08
EP2298298A3 (en) 2011-05-11
NO20013143D0 (en) 2001-06-22
RU2361575C2 (en) 2009-07-20
AU2006203077A1 (en) 2006-08-10
CA2622805A1 (en) 2000-07-06
PT1140071E (en) 2007-05-31
ID29856A (en) 2001-10-18
TR200605471T2 (en) 2006-11-21
NO20013143L (en) 2001-08-16
CN1331590A (en) 2002-01-16
SI1588706T1 (en) 2012-01-31
RU2005124363A (en) 2007-02-10
TR200805740T1 (en) 2010-06-21
RU2008143545A (en) 2010-05-10
EP1588706B1 (en) 2011-09-14
RU2271809C2 (en) 2006-03-20
AU2009220022A1 (en) 2009-10-15
HK1038888B (en) 2007-09-21
KR100646716B1 (en) 2006-11-17
BR9916576A (en) 2001-10-02
NO20100041L (en) 2001-08-16
CZ293257B6 (en) 2004-03-17
HK1038888A1 (en) 2002-04-04
TR200101784T2 (en) 2001-10-22
EP2298298A2 (en) 2011-03-23
DE69935249D1 (en) 2007-04-05
CA2622805C (en) 2011-05-10
DE69935249T2 (en) 2007-10-31
JP2002533390A (en) 2002-10-08
CN1304000C (en) 2007-03-14
JP5254258B2 (en) 2013-08-07
IL143233A (en) 2007-07-24
EP1588706A2 (en) 2005-10-26
EP1140071B1 (en) 2007-02-21
JP2010090169A (en) 2010-04-22
NO328775B1 (en) 2010-05-10
ES2281978T3 (en) 2007-10-01
DK1588706T3 (en) 2012-01-16
HUP0104780A2 (en) 2002-04-29
PL349424A1 (en) 2002-07-29
WO2000038676A1 (en) 2000-07-06
PL199100B1 (en) 2008-08-29
CZ20012306A3 (en) 2001-12-12
AU3043000A (en) 2000-07-31
SK9132001A3 (en) 2002-01-07
NZ587909A (en) 2012-05-25
IL179016A0 (en) 2007-03-08
CZ297795B6 (en) 2007-03-28
NZ511938A (en) 2004-02-27
EP1140071A1 (en) 2001-10-10
CY1112395T1 (en) 2015-12-09
SI1140071T1 (en) 2007-08-31
ATE354364T1 (en) 2007-03-15
NZ553010A (en) 2008-09-26
EP1588706A3 (en) 2005-12-07
ATE524176T1 (en) 2011-09-15
AU2003266433B2 (en) 2006-08-10
IL179017A0 (en) 2007-03-08
TR200605472T1 (en) 2007-02-21
PT1588706E (en) 2011-12-21
TR200805741T2 (en) 2008-10-21
TR200805275T2 (en) 2008-09-22
CY1106581T1 (en) 2012-01-25
TR200200764T2 (en) 2002-07-22
AU2006203077B2 (en) 2009-10-08
CN1636561A (en) 2005-07-13
HUP0104780A3 (en) 2002-11-28
AU2003266433A1 (en) 2004-01-08

Similar Documents

Publication Publication Date Title
IL179015A0 (en) Compressed tablet comprising valsartan
WO1999017755A3 (en) Medicaments
CA2353962A1 (en) Selective 5-ht6 receptor ligands
IL147977A0 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
WO2000012623A3 (en) Use of 5-th receptor antagonists for the treatment of parkinson's disease
IL119417A0 (en) Drug for Parkinson's disease
CA2295119A1 (en) Use of a specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
IL206566A0 (en) Use of an antagonist to the igs4 neuromedin receptor polypeptide for the preparation of a medicament for the treatment of a disease related to the expression or acitivity of the igs4 neuromedin receptor polypeptide
WO1999029308A3 (en) Method for combating obesity
AU9069291A (en) Use of angiotensin ii receptor antagonists for the preparation of a medicament for improving cognitive function
DE69318710D1 (en) Antitussivum
CA2260863A1 (en) Treatment of psychotic disorders
HUP0103864A3 (en) Use of 3-(1h-imidazol-4-ylmethyl)-indan-5-ol in the manufacture of a medicament for intraspinal administration
AU3808495A (en) Use of nk1 receptor antagonists for preparing cardio-regulatory drugs
SI1200402T1 (en) Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain
MX9710002A (en) Novel medical use.
IL123536A0 (en) 5-HT3 Receptor antagonists for dyskinesia
SI1148881T1 (en) USE OF PYRIDAZINO-(4,5-(b))-INDOLE-1-ACETAMIDE DERIVATIVES FOR PREPARING MEDICINES FOR TREATING DISEASES RELATED TO THE DYSFUNCTION OF PERIPHERAL BENZODIAZEPIN RECEPTORS